THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-GP INHIBITOR FOR THE TREATMENT OF CANCER

The application pertains to pharmaceutical combinations of orally administered paclitaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity -type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered paclitaxel (e.g., Taxol or paclitaxel formulated with Cremophor) therapy in a subject suffering from cancer. 本申请涉及口服给药的紫杉醇和P-gp抑制剂的药物组合。药物组合适用于治疗受试者的癌症，和减小或防止毒性、过敏型输液反应和由患有癌症受试者的静脉给药紫杉醇(例如，Taxol®或用Cremophor®配制的紫杉醇)治疗引起或与其相关的其它负面结果。